| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Re-Irradiation | 10 | 2021 | 166 | 4.260 |
Why?
|
| Radiotherapy, Intensity-Modulated | 33 | 2024 | 2178 | 3.570 |
Why?
|
| Head and Neck Neoplasms | 37 | 2024 | 4148 | 3.230 |
Why?
|
| Radiosurgery | 13 | 2024 | 1389 | 2.630 |
Why?
|
| Oropharyngeal Neoplasms | 25 | 2023 | 1162 | 2.400 |
Why?
|
| Nasopharyngeal Neoplasms | 8 | 2023 | 340 | 2.080 |
Why?
|
| Skull Base Neoplasms | 7 | 2022 | 339 | 1.910 |
Why?
|
| Nose Neoplasms | 4 | 2024 | 243 | 1.800 |
Why?
|
| Paranasal Sinus Neoplasms | 8 | 2024 | 294 | 1.780 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 5 | 2024 | 124 | 1.760 |
Why?
|
| Radiotherapy, Conformal | 5 | 2020 | 898 | 1.510 |
Why?
|
| Carcinoma, Squamous Cell | 25 | 2023 | 5603 | 1.460 |
Why?
|
| Maxillary Sinus Neoplasms | 4 | 2023 | 114 | 1.340 |
Why?
|
| Radiotherapy Setup Errors | 3 | 2020 | 85 | 1.340 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2024 | 10404 | 1.220 |
Why?
|
| Proton Therapy | 11 | 2021 | 1637 | 1.010 |
Why?
|
| Radiation Injuries | 9 | 2019 | 1476 | 0.870 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 13 | 2023 | 2459 | 0.870 |
Why?
|
| Larynx | 3 | 2020 | 147 | 0.810 |
Why?
|
| Radiotherapy Dosage | 17 | 2024 | 4020 | 0.810 |
Why?
|
| Lipodystrophy | 5 | 2006 | 39 | 0.810 |
Why?
|
| Carcinoma | 7 | 2023 | 2610 | 0.800 |
Why?
|
| Adipose Tissue | 8 | 2009 | 703 | 0.780 |
Why?
|
| Adipocytes | 5 | 2009 | 295 | 0.760 |
Why?
|
| Papillomavirus Infections | 10 | 2023 | 999 | 0.750 |
Why?
|
| Retrospective Studies | 55 | 2024 | 39954 | 0.740 |
Why?
|
| Induction Chemotherapy | 6 | 2021 | 679 | 0.720 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2019 | 340 | 0.720 |
Why?
|
| Immobilization | 2 | 2019 | 91 | 0.680 |
Why?
|
| Humans | 127 | 2024 | 270637 | 0.630 |
Why?
|
| Patient Positioning | 2 | 2019 | 195 | 0.610 |
Why?
|
| Organ Sparing Treatments | 3 | 2019 | 283 | 0.600 |
Why?
|
| Trigeminal Neuralgia | 1 | 2018 | 42 | 0.590 |
Why?
|
| Alphapapillomavirus | 5 | 2022 | 172 | 0.590 |
Why?
|
| Aged | 62 | 2024 | 73579 | 0.580 |
Why?
|
| Aged, 80 and over | 38 | 2024 | 31110 | 0.580 |
Why?
|
| Middle Aged | 68 | 2024 | 90495 | 0.580 |
Why?
|
| Disease-Free Survival | 16 | 2023 | 10268 | 0.580 |
Why?
|
| Nuclear Proteins | 8 | 2006 | 3435 | 0.570 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 508 | 0.560 |
Why?
|
| Laryngeal Neoplasms | 5 | 2019 | 530 | 0.550 |
Why?
|
| Male | 80 | 2024 | 128446 | 0.540 |
Why?
|
| Chemoradiotherapy | 6 | 2020 | 2037 | 0.540 |
Why?
|
| Orbital Neoplasms | 2 | 2015 | 234 | 0.530 |
Why?
|
| Nasal Cavity | 3 | 2024 | 155 | 0.530 |
Why?
|
| Tonsillar Neoplasms | 3 | 2022 | 81 | 0.520 |
Why?
|
| Skull Base | 5 | 2020 | 224 | 0.510 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2016 | 84 | 0.510 |
Why?
|
| Carcinoma, Adenoid Cystic | 3 | 2018 | 444 | 0.500 |
Why?
|
| Adult | 56 | 2024 | 82023 | 0.500 |
Why?
|
| Brachytherapy | 3 | 2011 | 1005 | 0.500 |
Why?
|
| Treatment Outcome | 34 | 2024 | 33840 | 0.490 |
Why?
|
| Papillomaviridae | 7 | 2023 | 636 | 0.470 |
Why?
|
| Female | 76 | 2024 | 148834 | 0.470 |
Why?
|
| Quality of Life | 7 | 2024 | 4806 | 0.460 |
Why?
|
| Organs at Risk | 4 | 2020 | 559 | 0.430 |
Why?
|
| Deglutition Disorders | 5 | 2022 | 487 | 0.420 |
Why?
|
| Mouth Neoplasms | 4 | 2021 | 735 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2021 | 16740 | 0.370 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 481 | 0.370 |
Why?
|
| Salvage Therapy | 6 | 2022 | 2124 | 0.370 |
Why?
|
| Dura Mater | 2 | 2024 | 85 | 0.370 |
Why?
|
| Survival Analysis | 15 | 2020 | 9278 | 0.360 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 208 | 0.340 |
Why?
|
| Young Adult | 20 | 2024 | 22238 | 0.330 |
Why?
|
| Combined Modality Therapy | 13 | 2019 | 9053 | 0.330 |
Why?
|
| Prospective Studies | 13 | 2024 | 13406 | 0.330 |
Why?
|
| Phosphatidate Phosphatase | 8 | 2006 | 17 | 0.330 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2024 | 291 | 0.320 |
Why?
|
| Rectal Diseases | 1 | 2009 | 57 | 0.320 |
Why?
|
| Cohort Studies | 10 | 2024 | 9450 | 0.320 |
Why?
|
| Lipid Metabolism | 4 | 2006 | 474 | 0.320 |
Why?
|
| Disease Progression | 6 | 2024 | 6880 | 0.310 |
Why?
|
| Survival Rate | 12 | 2021 | 12528 | 0.310 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2024 | 881 | 0.310 |
Why?
|
| Cisplatin | 5 | 2024 | 2508 | 0.300 |
Why?
|
| Insulin Resistance | 4 | 2006 | 718 | 0.300 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 144 | 0.300 |
Why?
|
| Cell Differentiation | 5 | 2005 | 4105 | 0.300 |
Why?
|
| Thyroid Neoplasms | 3 | 2024 | 1908 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2024 | 7786 | 0.290 |
Why?
|
| Huntington Disease | 1 | 2009 | 148 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2024 | 1691 | 0.290 |
Why?
|
| Prednisone | 1 | 2010 | 1034 | 0.290 |
Why?
|
| Tumor Burden | 4 | 2024 | 2033 | 0.290 |
Why?
|
| Chromosome Mapping | 3 | 2001 | 1648 | 0.290 |
Why?
|
| Follow-Up Studies | 16 | 2019 | 15274 | 0.280 |
Why?
|
| Gene Expression Regulation | 4 | 2009 | 4102 | 0.280 |
Why?
|
| Doxorubicin | 2 | 2011 | 3145 | 0.270 |
Why?
|
| Neoplasm Staging | 18 | 2022 | 14033 | 0.260 |
Why?
|
| Vincristine | 1 | 2010 | 1582 | 0.260 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2023 | 742 | 0.250 |
Why?
|
| Lymphatic Metastasis | 8 | 2022 | 4969 | 0.250 |
Why?
|
| Lymph Nodes | 4 | 2019 | 3081 | 0.250 |
Why?
|
| Prognosis | 16 | 2023 | 22527 | 0.230 |
Why?
|
| Cancer Survivors | 2 | 2022 | 745 | 0.220 |
Why?
|
| Energy Metabolism | 2 | 2006 | 984 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2013 | 1740 | 0.220 |
Why?
|
| Stents | 2 | 2020 | 1000 | 0.220 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2020 | 878 | 0.220 |
Why?
|
| Time Factors | 12 | 2021 | 12974 | 0.210 |
Why?
|
| Adolescent | 12 | 2020 | 32687 | 0.210 |
Why?
|
| Hodgkin Disease | 1 | 2011 | 1485 | 0.210 |
Why?
|
| Alternative Splicing | 2 | 2005 | 610 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 3245 | 0.210 |
Why?
|
| Brain Stem | 1 | 2023 | 185 | 0.200 |
Why?
|
| Fatty Liver | 3 | 2006 | 248 | 0.200 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 485 | 0.200 |
Why?
|
| Hypercholesterolemia | 2 | 2001 | 264 | 0.200 |
Why?
|
| Radiodermatitis | 2 | 2019 | 79 | 0.200 |
Why?
|
| Cervical Vertebrae | 2 | 2020 | 219 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 5246 | 0.190 |
Why?
|
| Hypersensitivity | 1 | 2024 | 216 | 0.190 |
Why?
|
| Radiation Oncology | 2 | 2016 | 557 | 0.190 |
Why?
|
| Taste Buds | 1 | 2020 | 8 | 0.190 |
Why?
|
| Microsatellite Repeats | 2 | 2000 | 627 | 0.190 |
Why?
|
| Pentoxifylline | 1 | 2020 | 38 | 0.180 |
Why?
|
| Metformin | 1 | 2024 | 397 | 0.180 |
Why?
|
| Laryngectomy | 3 | 2017 | 244 | 0.180 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 141 | 0.180 |
Why?
|
| Sarcoma | 2 | 2022 | 1851 | 0.180 |
Why?
|
| Xerostomia | 2 | 2019 | 205 | 0.180 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 64 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2017 | 2272 | 0.170 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 144 | 0.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 617 | 0.170 |
Why?
|
| Cetuximab | 2 | 2018 | 474 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2023 | 7916 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 114 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2023 | 551 | 0.170 |
Why?
|
| Osteoradionecrosis | 1 | 2020 | 128 | 0.160 |
Why?
|
| Bile Acids and Salts | 1 | 2001 | 270 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 4468 | 0.160 |
Why?
|
| Markov Chains | 1 | 2019 | 188 | 0.160 |
Why?
|
| Muscle, Skeletal | 4 | 2021 | 1175 | 0.160 |
Why?
|
| Chromosomes | 1 | 1999 | 325 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1493 | 0.160 |
Why?
|
| Parotid Neoplasms | 1 | 2019 | 150 | 0.160 |
Why?
|
| Glottis | 1 | 2019 | 68 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2020 | 1273 | 0.160 |
Why?
|
| Breakthrough Pain | 1 | 2018 | 18 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6255 | 0.150 |
Why?
|
| Neck Pain | 1 | 2018 | 41 | 0.150 |
Why?
|
| Metastasectomy | 1 | 2020 | 209 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2022 | 584 | 0.150 |
Why?
|
| Mice | 15 | 2009 | 35414 | 0.150 |
Why?
|
| Texas | 5 | 2016 | 6445 | 0.150 |
Why?
|
| Minocycline | 1 | 2019 | 189 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 211 | 0.140 |
Why?
|
| Neck Dissection | 2 | 2019 | 294 | 0.140 |
Why?
|
| Body Composition | 2 | 2021 | 600 | 0.140 |
Why?
|
| Vocal Cords | 1 | 2018 | 106 | 0.140 |
Why?
|
| Obesity | 4 | 2006 | 2888 | 0.140 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 2045 | 0.140 |
Why?
|
| PPAR gamma | 2 | 2009 | 224 | 0.140 |
Why?
|
| Facial Pain | 1 | 2016 | 21 | 0.140 |
Why?
|
| Olfactory Bulb | 1 | 2017 | 120 | 0.140 |
Why?
|
| Positron-Emission Tomography | 5 | 2022 | 2199 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 515 | 0.130 |
Why?
|
| Peer Review | 1 | 2016 | 82 | 0.130 |
Why?
|
| Thyroidectomy | 1 | 2019 | 489 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 497 | 0.130 |
Why?
|
| Steroids | 1 | 2018 | 372 | 0.130 |
Why?
|
| Treatment Failure | 5 | 2019 | 1429 | 0.130 |
Why?
|
| Radiation Dosage | 2 | 2018 | 1042 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 476 | 0.130 |
Why?
|
| Photons | 2 | 2018 | 536 | 0.130 |
Why?
|
| Pharyngeal Muscles | 1 | 2016 | 40 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 855 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2018 | 199 | 0.130 |
Why?
|
| Causality | 1 | 2016 | 173 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 5 | 2006 | 2419 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 517 | 0.130 |
Why?
|
| Radiotherapy | 3 | 2017 | 1858 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 631 | 0.130 |
Why?
|
| Palliative Care | 2 | 2018 | 2176 | 0.130 |
Why?
|
| Smoking | 3 | 2020 | 2546 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2009 | 5867 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2016 | 415 | 0.120 |
Why?
|
| Organic Chemicals | 2 | 2005 | 102 | 0.120 |
Why?
|
| Physical Examination | 1 | 2016 | 306 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 906 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 286 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 277 | 0.120 |
Why?
|
| Immunotherapy | 2 | 2019 | 3561 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2018 | 1260 | 0.120 |
Why?
|
| Cholesterol | 3 | 2003 | 656 | 0.120 |
Why?
|
| Animals | 16 | 2010 | 61340 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2009 | 5415 | 0.120 |
Why?
|
| Orbit | 1 | 2015 | 209 | 0.110 |
Why?
|
| Pain Measurement | 1 | 2018 | 1021 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 637 | 0.110 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2015 | 172 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 3463 | 0.110 |
Why?
|
| Risk Factors | 4 | 2020 | 17849 | 0.110 |
Why?
|
| Analgesics | 1 | 2016 | 406 | 0.110 |
Why?
|
| Prevalence | 2 | 2023 | 3392 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 327 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 4054 | 0.100 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2013 | 142 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 586 | 0.100 |
Why?
|
| 3T3 Cells | 2 | 2004 | 385 | 0.100 |
Why?
|
| Vomiting | 1 | 2014 | 359 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1656 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2020 | 2313 | 0.100 |
Why?
|
| Body Weight | 2 | 2009 | 1282 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 912 | 0.100 |
Why?
|
| Nausea | 1 | 2014 | 537 | 0.100 |
Why?
|
| Nomograms | 1 | 2014 | 312 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 593 | 0.100 |
Why?
|
| Physicians | 1 | 2020 | 853 | 0.100 |
Why?
|
| RNA, Messenger | 5 | 2005 | 6344 | 0.100 |
Why?
|
| Proteins | 1 | 1999 | 2030 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 959 | 0.090 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 633 | 0.090 |
Why?
|
| Vinblastine | 1 | 2011 | 462 | 0.090 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 100 | 0.090 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 4968 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 3582 | 0.090 |
Why?
|
| Neoplasm Metastasis | 4 | 2024 | 5332 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 14638 | 0.090 |
Why?
|
| Bleomycin | 1 | 2011 | 482 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2016 | 4007 | 0.090 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 601 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 4493 | 0.080 |
Why?
|
| Organ Specificity | 2 | 2009 | 734 | 0.080 |
Why?
|
| Comorbidity | 1 | 2016 | 2393 | 0.080 |
Why?
|
| Urination Disorders | 1 | 2009 | 63 | 0.080 |
Why?
|
| Glucose | 2 | 2005 | 1213 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2011 | 502 | 0.080 |
Why?
|
| Neoplasms | 3 | 2022 | 15949 | 0.080 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 4198 | 0.080 |
Why?
|
| Exons | 2 | 2005 | 1388 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1761 | 0.080 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2009 | 60 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 53 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 1331 | 0.080 |
Why?
|
| Adipokines | 1 | 2009 | 96 | 0.080 |
Why?
|
| Response Elements | 1 | 2009 | 192 | 0.080 |
Why?
|
| Gene Knock-In Techniques | 1 | 2009 | 183 | 0.080 |
Why?
|
| Retreatment | 2 | 2019 | 449 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2001 | 1406 | 0.080 |
Why?
|
| Incidence | 3 | 2020 | 5814 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 1467 | 0.070 |
Why?
|
| Mutation | 3 | 2019 | 15917 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2005 | 1715 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 878 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2022 | 2360 | 0.070 |
Why?
|
| Organ Size | 1 | 2009 | 686 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 359 | 0.070 |
Why?
|
| Thiazolidinediones | 2 | 2006 | 147 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 2477 | 0.070 |
Why?
|
| Stomatitis | 2 | 2018 | 190 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 342 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 84 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 4 | 2005 | 7047 | 0.060 |
Why?
|
| 3T3-L1 Cells | 1 | 2005 | 69 | 0.060 |
Why?
|
| Cell Line | 2 | 2005 | 5313 | 0.060 |
Why?
|
| Calorimetry | 1 | 2005 | 64 | 0.060 |
Why?
|
| Remission Induction | 1 | 2011 | 3658 | 0.060 |
Why?
|
| Rituximab | 1 | 2010 | 1594 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 6638 | 0.060 |
Why?
|
| Retroviridae | 1 | 2005 | 372 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 330 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2004 | 24 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2024 | 6231 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2009 | 7317 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2010 | 1184 | 0.060 |
Why?
|
| Introns | 1 | 2005 | 460 | 0.060 |
Why?
|
| Automation | 1 | 2024 | 154 | 0.060 |
Why?
|
| Cholates | 1 | 2003 | 1 | 0.060 |
Why?
|
| Diet, Atherogenic | 1 | 2003 | 19 | 0.060 |
Why?
|
| Pituitary Hormones | 1 | 2023 | 15 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 920 | 0.060 |
Why?
|
| Muscles | 1 | 2005 | 443 | 0.060 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 245 | 0.050 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2003 | 67 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 751 | 0.050 |
Why?
|
| Plasmids | 1 | 2005 | 923 | 0.050 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2002 | 20 | 0.050 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 31 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2005 | 843 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2023 | 151 | 0.050 |
Why?
|
| Endpoint Determination | 2 | 2016 | 179 | 0.050 |
Why?
|
| Chromosomes, Mammalian | 1 | 2002 | 62 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2024 | 176 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 107 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 768 | 0.050 |
Why?
|
| Logistic Models | 3 | 2016 | 3423 | 0.050 |
Why?
|
| Nanomedicine | 1 | 2022 | 53 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2009 | 1626 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2004 | 340 | 0.050 |
Why?
|
| DNA Primers | 2 | 2006 | 1489 | 0.050 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2001 | 15 | 0.050 |
Why?
|
| Steroid Hydroxylases | 1 | 2001 | 38 | 0.050 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2001 | 37 | 0.050 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 907 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 5093 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2023 | 654 | 0.050 |
Why?
|
| Radiation Hybrid Mapping | 1 | 2001 | 11 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 100 | 0.050 |
Why?
|
| Tocopherols | 1 | 2020 | 20 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2021 | 2225 | 0.050 |
Why?
|
| Multigene Family | 1 | 2002 | 469 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2005 | 1161 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 4391 | 0.050 |
Why?
|
| Radiography | 2 | 2016 | 1994 | 0.050 |
Why?
|
| Fatigue | 2 | 2019 | 1290 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2021 | 54 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 465 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 5916 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2021 | 101 | 0.040 |
Why?
|
| Tongue | 1 | 2020 | 86 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 209 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 404 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 214 | 0.040 |
Why?
|
| Cholesterol, Dietary | 1 | 2000 | 52 | 0.040 |
Why?
|
| Oxygen | 1 | 2005 | 786 | 0.040 |
Why?
|
| Sequence Tagged Sites | 1 | 1999 | 43 | 0.040 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 2000 | 53 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4315 | 0.040 |
Why?
|
| Templates, Genetic | 1 | 2000 | 127 | 0.040 |
Why?
|
| Contig Mapping | 1 | 1999 | 63 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 223 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 339 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2001 | 317 | 0.040 |
Why?
|
| Dental Impression Technique | 1 | 2019 | 16 | 0.040 |
Why?
|
| RNA | 1 | 2005 | 1057 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5594 | 0.040 |
Why?
|
| Hypertriglyceridemia | 1 | 2001 | 114 | 0.040 |
Why?
|
| Insulin | 1 | 2005 | 1423 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 251 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 135 | 0.040 |
Why?
|
| Temporal Bone | 1 | 2020 | 108 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 154 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2001 | 650 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 177 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2001 | 497 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2005 | 3567 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2019 | 111 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 556 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 183 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 726 | 0.040 |
Why?
|
| Leptin | 1 | 2001 | 302 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 1337 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 5048 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2005 | 1647 | 0.040 |
Why?
|
| Deglutition | 1 | 2020 | 187 | 0.040 |
Why?
|
| Endoscopy | 1 | 2022 | 495 | 0.040 |
Why?
|
| Alleles | 2 | 2005 | 2597 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 253 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 4892 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 709 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2024 | 1567 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 148 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 191 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 278 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3427 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 167 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2010 | 7232 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2019 | 246 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 780 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2016 | 6765 | 0.040 |
Why?
|
| Liver | 2 | 2006 | 3057 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 319 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 1562 | 0.040 |
Why?
|
| Time | 1 | 2017 | 182 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 12036 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2005 | 5657 | 0.040 |
Why?
|
| Survivorship | 1 | 2017 | 116 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1999 | 1073 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 364 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 315 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 561 | 0.030 |
Why?
|
| Teaching Rounds | 1 | 2016 | 37 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2001 | 866 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 307 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2016 | 449 | 0.030 |
Why?
|
| Diet | 1 | 2004 | 1468 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2017 | 230 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 32 | 0.030 |
Why?
|
| Genome | 1 | 2000 | 689 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1060 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 1042 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 731 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 2016 | 334 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 591 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 518 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 369 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 854 | 0.030 |
Why?
|
| Hospital Restructuring | 1 | 1995 | 1 | 0.030 |
Why?
|
| Hospitals, Religious | 1 | 1995 | 8 | 0.030 |
Why?
|
| Internet | 1 | 2000 | 687 | 0.030 |
Why?
|
| Total Quality Management | 1 | 1995 | 36 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 907 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 149 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 450 | 0.030 |
Why?
|
| Cervical Atlas | 1 | 2014 | 21 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 930 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 488 | 0.030 |
Why?
|
| Tonsillectomy | 1 | 2016 | 121 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 982 | 0.030 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10725 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 255 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2015 | 227 | 0.030 |
Why?
|
| Brain | 2 | 2020 | 4198 | 0.030 |
Why?
|
| Stem Cells | 1 | 2001 | 1212 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 4963 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 726 | 0.030 |
Why?
|
| Eyelid Neoplasms | 1 | 2015 | 193 | 0.030 |
Why?
|
| Lacrimal Apparatus | 1 | 2015 | 185 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 271 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2001 | 2157 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1065 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 638 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 677 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 2656 | 0.030 |
Why?
|
| Head | 1 | 2014 | 248 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 3534 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2002 | 5144 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2017 | 765 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 889 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1336 | 0.020 |
Why?
|
| Neck | 1 | 2014 | 394 | 0.020 |
Why?
|
| Weight Loss | 1 | 2016 | 626 | 0.020 |
Why?
|
| Gene Expression | 1 | 1999 | 3606 | 0.020 |
Why?
|
| Radiometry | 1 | 2017 | 1021 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 969 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 1995 | 319 | 0.020 |
Why?
|
| Lung | 1 | 2022 | 3287 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3054 | 0.020 |
Why?
|
| DNA | 1 | 2000 | 3041 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5436 | 0.020 |
Why?
|
| Models, Biological | 1 | 2019 | 3186 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2015 | 867 | 0.020 |
Why?
|
| Pain | 1 | 2019 | 1701 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1344 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1095 | 0.020 |
Why?
|
| Cornea | 1 | 2015 | 681 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 6502 | 0.020 |
Why?
|
| Self Report | 1 | 2014 | 793 | 0.020 |
Why?
|
| Survivors | 1 | 2015 | 1021 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6192 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1999 | 2922 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 461 | 0.020 |
Why?
|
| Research Design | 1 | 2016 | 1559 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 7646 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 1547 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2570 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3903 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 5405 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 2208 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1342 | 0.020 |
Why?
|
| Child | 2 | 2020 | 30558 | 0.020 |
Why?
|
| Fatty Acid Synthases | 1 | 2006 | 26 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2006 | 57 | 0.020 |
Why?
|
| Glycogen | 1 | 2006 | 82 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 1931 | 0.020 |
Why?
|
| Thinness | 1 | 2005 | 78 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 706 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 494 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 783 | 0.010 |
Why?
|
| Acute Disease | 1 | 2009 | 2491 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 17071 | 0.010 |
Why?
|
| Serum Amyloid A Protein | 1 | 2003 | 39 | 0.010 |
Why?
|
| Aldo-Keto Reductases | 1 | 2002 | 3 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 908 | 0.010 |
Why?
|
| Aldehyde Reductase | 1 | 2002 | 23 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2002 | 78 | 0.010 |
Why?
|
| Dyslipidemias | 1 | 2005 | 241 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 931 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 1072 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2003 | 523 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2000 | 16 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 723 | 0.010 |
Why?
|
| Fibrosis | 1 | 2003 | 715 | 0.010 |
Why?
|
| Phylogeny | 1 | 2002 | 854 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 2000 | 221 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 2336 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2000 | 603 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 3490 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 5692 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2000 | 577 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4532 | 0.010 |
Why?
|
| Aorta | 1 | 2000 | 666 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 3472 | 0.010 |
Why?
|
| Decision Making, Organizational | 1 | 1995 | 8 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 2491 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1995 | 824 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 5776 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 16242 | 0.000 |
Why?
|